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A B S T R A C T   
Limb-girdle muscular dystrophy recessive 1 (LGMDR1) represents one of the most common types of LGMD in the 
population, where patients develop a progressive muscle degeneration. The disease is caused by mutations in 
calpain 3 gene, with over 500 mutations reported to date. However, the molecular events that lead to muscle 
wasting are not clear, nor the reasons for the great clinical variability among patients, and this has so far hin-
dered the development of effective therapies. Here we generate human induced pluripotent stem cells (iPSCs) 
from skin fibroblasts of 2 healthy controls and 4 LGMDR1 patients with different mutations. The generated lines 
were able to differentiate into myogenic progenitors and myotubes in vitro and in vivo, upon a transient PAX7 
overexpressing protocol. Thus, we have generated myogenic cellular models of LGMDR1 that harbor different 
CAPN3 mutations within a human genetic background, and which do not derive from muscular biopsies. These 
models will allow us to investigate disease mechanisms and test therapies. Despite the variability found among 
iPSC lines that was unrelated to CAPN3 mutations, we found that patient-derived myogenic progenitors and 
myotubes express lower levels of DMD, which codes a key protein in satellite cell regulation and myotube 
maturation.   
1. Introduction 
Limb-girdle muscular dystrophy recessive 1 (LGMDR1), previously 
known as LGMD2A (OMIM: 253600), is a genetically defined muscular 
dystrophy that presents an autosomal recessive inheritance pattern. 
Disease-causing mutations affect to CAPN3 gene, which encodes the 
proteolytic enzyme calpain 3 (CAPN3). LGMDR1 affects 1 to 9 cases per 
100,000 people, and it represents almost 30% of the LGMD cases in the 
population (Richard et al., 1995; Straub et al., 2018). The prevalence is 
considerably higher in specific regions of the world, such as the Spanish 
province of Gipuzkoa, where 79% of the LGMD cases are type R1, having 
one of the highest prevalence in the world (Urtasun et al., 1998). There 
are more than 500 pathogenic mutations reported to date (LOVD, 2020), 
and although there seems to be a correlation between the type of 
mutation and the severity of the disease, clinical outcome cannot be 
predicted yet by the mutations found in each patient (Sáenz et al., 2011). 
In general, the disease is clinically characterized with a slow progressive 
muscular weakness that affects both pelvic and scapular girdles, as well 
as proximal lower limb muscles (Fardeau et al., 1996). Symptoms usu-
ally appear during the second decade of life and lead to the loss of 
ambulation within one or two decades after onset. Despite gene therapy 
approaches have been tested preclinically during the last two decades, 
currently there are no treatments available and only palliative care can 
be offered to the affected patients (Straub and Bertoli, 2016). 
Calpain 3 may play multiple roles in the adult skeletal muscle and it 
seems to be crucial for the maintenance of the sarcomere homeostasis 
and calcium regulation in the triads (Lasa-Elgarresta et al., 2019). 
However, the functional complexity of this protein hinders the 
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elucidation of a clear pathological mechanism at the molecular level. 
Up to date, patient muscle tissue has been very valuable to study the 
disease. However, biopsies are scarce and primary myoblast cultures can 
only be extended to a limited amount of passages. Alternatively, animal 
models of LGMDR1 remain as a valuable tool to understand some dis-
ease mechanisms, but they do not fully represent the disease patho-
physiology due to differences in development, metabolism and genetic 
background, generally developing a much milder phenotype (Lostal 
et al., 2019). 
Patient-derived induced pluripotent stem cells (iPSCs) represent a 
great opportunity to recapitulate disease pathogenicity in a mutation 
specific manner. These cells can be expanded indefinitely in vitro, 
differentiated potentially into any type of mature cell, and they also 
allow to develop disease-specific models, test therapeutic strategies, 
perform toxicity screenings and become potential sources for cell 
transplantation therapy (Tiscornia et al., 2011). 
Myogenic differentiation of iPSCs can be achieved through exoge-
nous expression of myogenic genes such as MYOD (Maffioletti et al., 
2015) and PAX7 (Darabi et al., 2012). Altered regeneration capacity and 
satellite cell pool have also been described in LGMDR1 patients (Rosales 
et al., 2013; Yalvac et al., 2017). Therefore, the PAX7 overexpression 
approach was followed in order to try to recapitulate early myogenic 
events more accurately. Following this myogenic strategy, a CRISPR/ 
Cas9 mediated gene correction approach has been recently developed 
for CAPN3 mutations in LGMDR1 patient-derived iPSCs, where CAPN3 
expression was restored in differentiated myotubes (Selvaraj et al., 
2019). 
In this study, we describe the generation of in vitro myogenic models 
from four LGMDR1 patient-derived iPSCs with a set of different muta-
tions. The developed iPSC lines attain pluripotency characteristics and 
despite mutations in calpain 3, they are able to differentiate into myo-
tubes both in vitro and in vivo following a transient Pax7 overexpression 
protocol. These models showed that calpain 3 is induced in the differ-
entiation process towards a mature form of the culture. While the lines 
had a variable myogenic potential, the differences could not be directly 
attributed to CAPN3 mutations. DMD expression was significantly 
reduced in patient-derived cultures, both before and after the terminal 
myogenic differentiation, indicating that DMD could play a role in 
LGMDR1. Overall, this work provides tools to advance our under-
standing of the pathological mechanisms of different CAPN3 mutations 
in a human myogenic context and they could be used to test different 
therapeutic approaches to treat LGMDR1. 
2. Methods 
2.1. Human biological samples 
Four LGMDR1 patients from the Neuromuscular Unit of Neurology 
Service of the Donostia University Hospital were selected to participate 
in this study based on the mutations in CAPN3 gene and their disease 
phenotype. Patients were graded according to an adapted version of the 
Vignos and Archibald Scale (Walton et al., 1994). Participants signed an 
informed consent prior to the skin sample collection for fibroblast 
expansion. Two age- and sex-matched healthy donor-derived fibroblasts 
were obtained from the Basque Biobank to be used as controls for this 
study. Absence of mutations in the CAPN3 gene was ascertained in these 
two samples. All procedures described here were reviewed and 
approved by the Ethics Committee of Clinical Investigation from 
Euskadi, and the Guarantee Commission for the Donation of Human 
Cells and Tissues at The Institute of Health Carlos III, following the 
guidelines of the Law 14/2007 for biomedical research. 
2.2. Reprogramming of fibroblasts and iPSC culture 
pMSCV-based retroviral vectors expressing FLAG-tagged OCT4, 
SOX2, KLF4 and cMYCT58A were used to produce retroviruses in 
Phoenix Amphotrophic cells, as previously described (Swift et al., 1999). 
Cell supernatants carrying the four reprogramming retroviruses were 
used for infection by centrifugation at 700 g for 45 min at 32 ◦C, using 1 
μg/mL of polybrene as transfection reagent. 24 h later, a second infec-
tion was performed following the same procedure. 72 h after the second 
infection, fibroblasts were seeded on top of irradiated feeder cells and 
48 h later the medium was switched to human embryonic stem cell 
medium (hES medium: KnockOut DMEM medium supplemented with 
20% KnockOut Serum Replacement, 2 mM GlutaMAX, 1x non-essential 
amino acids (NEAA) solution, 50 μM 2-mercaptoethanol, 100 U/mL 
penicillin, 100 μg/mL streptomycin and 10 ng/mL FGF2). This medium 
was replaced daily until colonies of reprogrammed cells appeared on top 
of the feeder cell layer. Clones were selected from each individual by 
expanding independent colonies. At passage 6 or higher, iPSCs were 
adapted to feeder-free conditions by seeding them on matrigel-coated 
wells and culturing them with mTeSR1 medium supplemented with 
100 U/mL penicillin and 100 μg/mL streptomycin. Cells were expanded 
using ReLeSR reagent and culture medium was supplemented with 5 μM 
Y-27632 rock inhibitor for 24 h after each passage. 
2.3. Myogenic differentiation of iPSCs 
To generate myogenic progenitors, iPSCs were transduced with a 
doxycycline inducible PAX7 system comprised of pSAM2-iPAX7-ires- 
GFP and FUGW-rtTA lentiviral vectors, as previously described (Dar-
abi et al., 2012). To induce myogenic terminal differentiation, myogenic 
progenitors were plated on 0.1% gelatin-coated wells and allowed to 
grow to 100% confluency. Then, cells were cultured for 5 more days in 
differentiation medium consisting on low glucose DMEM (Gibco) sup-
plemented with 15% KnockOut Serum Replacement (Gibco), 2 ng/mL 
IGF (Sigma-Aldrich) and 10 ng/mL HGF (Merck-Millipore). 
2.4. RNA analysis 
RNA was extracted with the RNeasy mini kit (Qiagen) and 1 μg of 
RNA was retrotranscribed using the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosciences), following manufacturer’s in-
structions. Dystrophin, calpain 3, Myogenin, MYH3, and MYH2 gene 
expression were assessed using TaqMan probes (AppliedBiosystems) 
(Supp. Table 1). Analysis of CAPN3 maturation along the differentiation 
process of healthy control samples was performed at day 0, 2 and 5 of 
differentiation. Expression results were normalized to 100%, which was 
calculated by summing the expression rate of the immature isoform 
(lacking exon 6, delta exon 6) and the mature isoform (probe for exons 
5–6) at each timepoint. 
2.5. Western blot 
Differentiated cultures at day 5 were lysed in lysis buffer, protein 
extracts were heated at 95 ◦C for 3 min, and 40 μL of each protein extract 
were loaded into 8% acrylamide gels. Human muscle protein extracts 
were used as a positive control. After electrophoresis, proteins were 
transferred to Hibond Nitrocellulose membranes and blocked with 5% 
skimmed milk diluted in TBST solution shaking for 1 h at room tem-
perature (RT). Subsequently, membranes were incubated overnight 
(ON) with primary antibodies (Anti-calpain 3: Cosmobio, COP-080049, 
1:1000; anti-GAPDH: Cell Signaling Technology, 2118, 1:10000) diluted 
in 5% BSA in TBST. The following day, membranes were incubated in 
secondary antibody diluted in 5% skimmed milk in TBST. Finally, pro-
teins were detected by chemiluminescence using the SuperSignal West 
Dura kit. Protein levels were assessed using Image Studio Lite 5.2, and 
standardized to GAPDH protein levels. 
2.6. Immunofluorescence analysis 
Cultured cells were fixed in 4% PFA for 10 min at RT and 
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permeabilized with 0.3% triton X-100 in PBS for 20 min. Next, samples 
were blocked with 10% donkey serum and 0.01% triton X-100 diluted in 
PBS for 1 h at RT, and then incubated with the primary antibody (Anti- 
MYHC: MF20, DSHB, 1:50; anti-Myogenin: F5D, DSHB, 1:50) diluted in 
PBS with 0,3% triton X-100 ON at 4 ◦C. The following day, cells were 
incubated with the secondary antibody (DonkeyαMouse –Alexa Fluor 
555, Invitrogen A-31570, 1:500) diluted in PBS for 1 h at RT, protected 
from light. Finally, samples were incubated for 3 min in 1 μg/mL 
Hoechst, and mounted using the Fluorogel mounting medium (EMS). 
For the detection of human iPSC-derived progenitor engraftment in 
the mice muscles, muscles were cryosectioned at 7 μm-thick sections. 
Sections were let at RT for 30 min, rehydrated in DPBS, permeabilized in 
0.3% triton X-100 in DPBS for 20 min, and blocked in 3% BSA in DPBS 
for 1 h at RT. Samples were incubated ON at 4 ◦C with the primary 
antibody (Anti-human dystrophin NCL- DYS3, Leica; 1:20) diluted in 
blocking solution. The following day, samples were incubated for 1 h at 
RT with the second primary antibody (Anti-human lamin A/C 
ab108595, Abcam, 1:500), diluted in blocking solution. Thereafter, 
samples were incubated for 45 min at RT with secondary antibodies 
(DonkeyαMouse Alexa Fluor 555 Invitrogen, A-31570, 1:500; Don-
keyαRabbit Alexa Fluor 488 Invitrogen, A-21206, 1:500) diluted in 
blocking solution. Finally, samples were incubated with 1 μg/mL 
Hoechst for 3 min to stain cell nuclei, and mounted with a coverslip 
using Fluorogel as mounting medium (EMS). 
2.7. In vivo myogenic differentiation assessment 
Transplantation of iPSC-derived muscle progenitor cells was per-
formed on NSG (NOD.Cg- Prkdcscid Il2rgtm1Wjl/SzJ, from Charles 
River) mice. All procedures were performed following the guidelines 
and approval from Biodonostia Animal Care Committee. At 8 weeks of 
age, both tibialis anterior (TA) muscles were injured by injecting 7.5 μL 
of 100 μM cardiotoxin (Sigma) using a beveled 26G needle. The 
following day, patient 1 and control 2-derived 106 progenitor cells at 
passage 4 post-sorting were transplanted into the right TA of each ani-
mal in 15 μL of volume. 15 μL of DPBS were injected into the left TA of 
each mouse and these muscles were used as negative controls. Mice were 
housed in the animal facility for 30 days before they were sacrificed. 
2.8. Assessment of statistical significance 
Statistical analysis was conducted using GraphPad Prism 5 software. 
An unpaired t-test with Welch’s correction and with a 0.05 significance 
level was used to analyze Myogenin percentage differences. A Mann- 
Whitney U test with a 0.05 significance level was used to analyze gene 
expression differences. A Friedman test with a 0.05 significance level 
was used to assess the evolution of expression rates of each CAPN3 
isoform. 
3. Results 
3.1. Generation of iPSCs from healthy individuals and LGMDR1 patients. 
In this study, two healthy controls and four LGMDR1 patient samples 
were used. Patient samples were obtained from individuals with a dis-
ease progression that ranged between intermediate and severe at the 
moment of the biopsy, according to the modified MVA scale. These were 
selected as representatives of the wide phenotypic and genetic vari-
ability found among LGMDR1 patients. Mutations in CAPN3 were het-
erozygous for patients 1–3, with complete gene deletions, single 
nucleotide mutations and deletions/insertions (delins), while patient 4 
was homozygous for a delin on exon 22, the most common mutation in 
the Basque population with LGMDR1 (Table 1). 
Primary fibroblasts at low passages derived from skin biopsies were 
used for reprogramming. The four Yamanaka factors OCT4, SOX2, KLF4 
and cMYC were expressed in the cells by infection with retroviral vectors 
and 3 to 6 weeks after seeding them on top of feeder cells, colonies 
resembling embryonic stem cell morphology were visible. iPSC colonies 
from each individual sample were sub-cultured and evaluated at genetic 
and cellular level to confirm successful reprogramming. One indepen-
dent clone was selected per individual as the final iPSC line. Pluripo-
tency was analysed in the final iPSC lines by the detection of alkaline 
phosphatase activity, pluripotency markers by immunofluorescence and 
gene expression, and the ability of the iPSC lines to differentiate into 
derivatives of the three primordial germ layers (Supp. Fig. 1A-D). 
Reprogramming of the lines was also confirmed at the epigenetic level 
by evaluating the methylation of CpG islands located at the promoter 
regions of pluripotency genes OCT4 and NANOG. The iPSC lines showed 
92–100% of the CpG islands unmethylated for OCT4 and 64–95% for 
NANOG (Supp. Fig. 2A-B), indicating that these genes were not 
repressed at the epigenetic level as they are in differentiated cells. 
Finally, karyotype stability through G-banding was evaluated to 
circumvent any chromosomal abnormalities (Supp. Fig. 2C). STR anal-
ysis and CAPN3 sequencing confirmed the identical genetic background 
of donor fibroblasts and the described iPSC clones (Supp. Info). Overall, 
the generated iPSC lines maintained the pluripotency state in a stable 
manner; they did not show any chromosomal or epigenetic abnormality 
and the pluripotency characteristics from healthy individual’s iPSC were 
indistinguishable from the patient-derived ones. 
3.2. Myogenic potential of iPSC-derived progenitors in vitro and in vivo 
In order to study LGMDR1 phenotype in iPSC-derived myotubes, we 
performed myogenic differentiation through doxycycline inducible 
Pax7 overexpression (Fig. 1A). After Pax7+ cell sorting (Supp. Fig. 3), 
myogenic progenitors at day 0 of in vitro differentiation presented little 
expression of myogenic genes with no statistically significant differences 
except for embryonic myosin (MYH3), whose expression was increased 
in patient-derived progenitor cells compared to control-derived cells, 
but with a very low total level (Supp. Fig. 4). However, at day 5 of 
terminal differentiation, in vitro differentiated progenitors from both 
Table 1 
Summary of clinical and molecular data available from sample donors.  
Sample Age Sex Origin of skin biopsy MVA grade Phenotype Mutated site DNA mutation Protein mutation 
Control 1 49 Female Breast – Healthy – – – 
Control 2 27 Male Foreskin – Healthy – – – 
Patient 1 22 Female Lower back 4 Severe Entire gene 
EX24 
Complete deletion 
c.2465G > T 
Absent 
X822Leuext62* 
Patient 2 33 Male Buttock 4 Advanced EX11 
EX22 




Patient 3 27 Male Proximal arm 3 Intermediate EX5 
EX16 
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Fig. 1. Myogenic differentiation of iPSCs in vitro and in vivo. A) Schematic representation of the myogenic differentiation of iPSCs. B) Immunofluorescence detection 
of MYHC (red, line 1) and Myogenin (red, line 2 and 3) in cell cultures at day 5 of terminal differentiation, and the Myogenin positive cell quantification graphs (line 
4). Scale bars: 100 µm. C) Bar graph illustrating GAPDH-relative myogenic gene expression rates in differentiated (day 5) cultures. D) Schematic representation of the 
intramuscular (IM) transplantation and regeneration experiment. E) Immunofluorescence images of TA crossections of mice transplanted with control-2 and patient- 
1-derived muscle progenitor cells. Detection of human lamin A/C positive cell nuclei (green) and human dystrophin-positive fibers (red). Scale bar: 50 µm. Cell nuclei 
are stained in Hoechst (blue). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) 
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control and LGMDR1 patient-derived lines were spindle-shaped and 
showed mature myotube protein marker expression such as Myogenin 
and MYHC (Fig. 1B), and Myogenin, MYH3 and MYH2 myogenic gene 
expression (Fig. 1C). No significative differences were observed between 
control and patient-derived cell lines, and a variable differentiation 
capacity was observed between the different cell lines, which seemed 
irrespective of the mutations harbored in CAPN3 gene (Fig. 1B-C). 
PAX7-expressing cells at passage 4 post-sorting were transplanted 
into cardiotoxin-injured TA muscles of immunodeficient mice in order to 
assess the in vivo myogenic potential of the iPSC-derived progenitors 
(Fig. 1D). For this experiment, patient-1 and the age matched control-2- 
derived cells were transplanted. 30 days after transplantation, TA 
muscles of injected animals were collected and analysed to assess the 
regenerative potential of the transplanted cells. Immunofluorescence 
staining of human lamin A/C allowed the detection of human cell nuclei 
engrafted in the mouse tissue, derived from transplanted cells (Fig. 1E). 
Similarly, human dystrophin expressing fibers could be detected, indi-
cating that both control and LGMDR1 patient-derived myogenic pro-
genitors could participate in the in vivo muscle fibre regeneration 
(Fig. 1E). In this experiment, patient-1-derived progenitors showed 
higher myogenic potential (data not shown), in accordance with the 
difference that could be observed in the in vitro experiment (Fig. 1B-C). 
3.3. Calpain 3 expression in iPSC-derived cultures 
Once the myogenic potential of the lines was verified, induction of 
calpain 3 expression was checked. At mRNA level, calpain 3 expression 
was assessed in control cultures and in the H9 human embryonic stem 
cell line, which was included as a positive differentiation control. Cal-
pain 3 could be already detected at day 0 of differentiation, and 
increased at day 5 as the cultures matured in control-1 and H9 lines 
(Fig. 2A). This was not the case in control-2-derived cultures, which 
correlated with the poor differentiation potential observed in the 
myogenic potential assessment both in vitro and in vivo (Fig. 1B-C and D). 
It has been described that several splicing variants of CAPN3 lacking 
exon 6 and/or exon 15 and exon 16 are detected during developmental 
stages, as well as during regenerative processes. This switch from 
immature to mature isoforms is recapitulated during in vitro myogenic 
differentiation (Herasse et al., 1999). To test this in the iPSC-derived 
myogenic model, the proportion of immature calpain 3 (lacking exon 
6) and mature calpain 3 (including exon 6) isoforms were studied at day 
0, 2 and 5 of the terminal differentiation process (Fig. 2B). The pro-
portion of the immature isoform (lacking exon 6) was progressively 
reduced, while the mature form (including exon 6) increased as differ-
entiation proceeded in control-1 and H9-derived cells. Here again, this 
change could not be observed in the poorly differentiating control-2- 
derived cells. 
Then, CAPN3 gene expression levels were analyzed by qPCR in 
controls and patients-derived PAX7 + progenitor cells and in terminally 
differentiated cultures (Fig. 2C). qPCR analysis results corroborated that 
CAPN3 expression was induced following differentiation. Interestingly, 
CAPN3 rates for each cell line varied greatly and they did not correlate 
strictly with the differentiation efficiency of each cell line (Fig. 1B). In 
this line, CAPN3 protein levels were assessed by western blot in in vitro 
differentiated cultures of control and patient-derived cell lines, using 
healthy human muscle extract as a control. The 94 KDa band corre-
sponding to full-size calpain 3 could be detected in all the differentiated 
cultures (Fig. 2D). P4, which contains an homozygous mutation in exon 
22, known as the Basque mutation, resulted in very low levels of 94 kDa 
calpain 3 band consistent with the absence of the 94 kDa calpain 3 band 
in muscle extracts of patients with the Basque mutation in homozygosis 
(data not shown). Current available calpain 3 antibodies are not 
completely specific and additional bands are detected, some of which 
are known to correspond to calpain 3 autoproteolytic products, whereas 
other bands might be nonspecific. 
3.4. Reduced DMD expression in patient-derived cultures 
LGMDR1 patients have an increased number of Pax7 + satellite cells 
as the disease progresses and fibrosis increases (Rosales et al., 2013), 
which indicates that satellite cell functioning and regeneration could be 
affected by mutations in calpain 3. Dystrophin, besides maintaining 
membrane integrity, it participates regulating asymmetric division of 
satellite cells, which is required for proper muscle regeneration. Dys-
trophin expression is significantly upregulated in quiescent satellite cells 
and it decreases upon satellite cell activation (Dumont et al., 2015). 
We studied DMD gene expression through qPCR in our control and 
patient-derived cell lines and found that DMD gene expression was 
reduced in patient-derived cultures compared to healthy control- 
derived cultures, both in PAX7 + progenitor cells and in terminally 
differentiated cultures (Fig. 3). 
4. Discussion 
Despite the genetic cause of LGMDR1 has been known for more than 
two decades, the exact pathophysiological mechanisms by which CAPN3 
mutations lead to the disease are still unknown (Zatz and Starling, 
2005). The different functions that have been attributed to calpain 3 
seem to be specifically compromised by each type of mutation, and are 
probably affecting the disease progression. Thus, understanding the 
pathogenic mechanisms could help in the development of therapies. 
Here we show the successful generation of iPSC lines from four LGMDR1 
patients with different mutations affecting calpain 3 and with a varying 
degree of disease progression at the time of the biopsy, as well as 2 age- 
and sex- matched healthy controls. The generated iPSC lines maintained 
genomic integrity and pluripotency characteristics in a stable manner, 
and differences in reprogramming efficiency among patient- and 
control-derived lines were not appreciated. 
Despite mutations in calpain 3, patient-derived lines were able to go 
through a myogenic differentiation process upon Pax7 overexpression in 
vitro and in vivo. This myogenic protocol led to myotube maturation over 
time, increased calpain 3 expression, and induced its mature isoform. 
However, variability in the myogenic potential of the generated iPSC 
lines seemed to be calpain 3 independent. This was evident in the in vitro 
differentiation potential of control-1 and control-2-derived cultures-, as 
well as in their calpain 3 expression pattern. On the other hand, the 
variability observed between the patients’ samples could be either due 
to the different mutations they harbor in CAPN3, or due to other tech-
nical factors related to their pluripotency level that were not detected. A 
possible explanation for this is that despite the exhaustive assessment of 
the pluripotency characteristics of the lines, it has been described that 
iPSCs can retain strong epigenetic marks that could directly affect their 
differentiation potential (Hiler et al., 2015). This means that in order to 
properly compare different iPSC lines, the epigenetic background should 
be more thoroughly analyzed and only cell lines with comparable 
epigenetic background should be used in comparative studies to avoid 
the variability derived from the epigenetic regulation. 
Traditionally, DMD has been considered as a terminal differentiation 
and maturation marker, but it has also been described as a regulator of 
satellite cell activity, regulating their asymmetric division during muscle 
regeneration. Absence of DMD leads to a reduced generation of 
myogenic progenitors (Dumont et al., 2015). In LGMDR1 patients, 
Pax7+ satellite cells increase with disease progression and fibrosis 
(Rosales et al., 2013), which suggests calpain 3 could be involved in 
satellite cell activation and differentiation. Interestingly, DMD was 
found downregulated in our patient-derived lines compared to controls 
both in progenitor and differentiated states, which suggests DMD 
regulation could be also affected in LGMDR1 satellite cells, perhaps 
compromising the asymmetric cell division and leading to a poor 
regeneration and accumulation of satellite cells. At the same time, lower 
DMD expression in regenerating myotubes could also be affecting 
maturation of LGMDR1 fibers, which in patient biopsies appear irregular 
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Fig. 2. Calpain 3 expression in iPSC-derived 
cultures. A) Quantification of total CAPN3 
expression (probe against exon 1–2 junction) 
in iPSC-derived cultures of control-1, control-2 
and H9-derived cells at day 0, 2 and 5 of ter-
minal differentiation, expressed as fold in-
duction of the expression level at day 0. B) 
Percentage of immature CAPN3 isoform 
(lacking exon 6) versus mature CAPN3 isoform 
(including exon 6) at day 0, 2 and 5 of dif-
ferentiation. Bars in A and B represent mean 
values and standard deviation of 3 experi-
mental replicates. C) Bar graph illustrating 
GAPDH-relative CAPN3 gene expression rates 
(probe against exon 1–2 junction) in undif-
ferentiated (progenitors day 0) and differenti-
ated (day 5) cultures. D) Western blot of 
calpain 3 protein detection using the IS2 
antibody and GAPDH as endogenous control 
(lower blot) in protein extracts of cell cultures 
at day 5 of terminal differentiation, and the 
quantification graph. Both blots correspond to 
a single gel and membrane. * p < 0.05.   
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in shape and variable in size (Rosales et al., 2013). 
In summary, we have generated four iPSC lines from LGMDR1 pa-
tients with a set of different mutations in calpain 3, and we have shown 
the ability of these lines to differentiate into myogenic progenitors 
through a PAX7 overexpressing myogenic protocol, and into myotubes 
both in vitro and in vivo. Interestingly, DMD expression was significantly 
reduced in patient-derived progenitors and differentiated myotubes, 
indicating a possible interplay between calpain 3 and DMD. 
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